SunTrust Reiterates Hold Rating on Humana (HUM) Following Announced Enclara Acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- SpaceX shares fall as second lockup period ends
- Supermicro probe finds no senior management link to export violations
- Werewolf Therapeutics sells platform assets to EMD Serono for $33M
Humana (HUM) to Acquire Enclara Healthcare
December 16, 2019 6:30 AM ESTHumana Inc. (NYSE: HUM) today announced it has signed a definitive agreement to acquire privately held Enclara Healthcare (Enclara), one of the nations largest hospice pharmacy and benefit management providers, from Consonance Capital Partners and Enclara management. Enclara is a leading pharmacy solutions provider focused on simplifying care delivery in complex care populations to improve patient experience, quality and cost.
The Enclara acquisition provides Humana with the opportunity to extend its comprehensive care continuum strategy to cover the pharmacy-related needs associated... More
Humana (HUM) PT Raised to $397 at Goldman Sachs
December 16, 2019 6:01 AM ESTGoldman Sachs raised its price target on Humana (NYSE: HUM) to $397.00 (from $358.00) while maintaining a Buy rating.... More
